

YYB-103

CellabMED Inc.



ONCOLOGY	Phase 1
Product Type	Cell and gene therapy
Indication	Glioblastoma (GBM)
Target	IL13R α 2(Interleukin-13 receptor alpha 2)
MoA(Mechanism of Action)	YYB-103 attacks the IL13R α 2-expressing tumor cells. YYB-103 recognizes tumor specific antigen IL13R α 2 and directly kills the target tumor cells.
Competitiveness	Versatile and applicable : YYB-103 binds selectively to IL13R α 2, which is found in various cancers, including glioblastoma, which is expressed in 40~60% of GBM patients. Highly Selective to tumor : YYB-103 has the modified IL-13 ligand which has mutated receptor binding sites to increase its selectivity for IL13R α 2 while reducing its binding affinity for IL13R α 1 expressed on normal cells.
Development Stage	Phase I
Route of Administration	IV administration, single dose